article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.

Marketing 100
article thumbnail

Leading pharmaceutical solid dose (commercial dose) manufacturing companies in contract marketing

Pharmaceutical Technology

Pharmaceutical solid dosage forms are the most popular in the pharmaceutical industry and are one of the most used drug delivery methods across patient groups. Pharmaceutical solid dose manufacturing companies in contract marketing segment have gained a vital position in pharmaceutical formulations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future's bright for Vetter - from lessons during the pandemic to maintaining a happy team

BioPharma Reporter

OSP was delighted to talk to Vetterâs Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.

article thumbnail

Alphabet’s Verily wields the axe, cutting staff and projects

pharmaphorum

The life sciences unit of Google parent Alphabet – which raised $1 billion back in September to fund its precision health agenda and business development activities, including possible acquisitions – said the move would allow it to streamline its operations.

article thumbnail

TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer

The Pharma Data

MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development. Earlier in his career, he ran business-development functions at Amgen and Baxter.

article thumbnail

Swissmedic approves Buvidal for the treatment of opioid dependence

The Pharma Data

Opioid dependence is a serious, chronic, relapsing disease associated with a disproportionate amount of drug-related harm that includes infectious diseases and other health problems, mortality, unemployment, homelessness and social exclusion 6. Fredrik Joabsson, Chief Business Development Officer Tel. +46 About Buvidal.

article thumbnail

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

The Pharma Data

LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.